Their ability to modulate STAT signaling in a context-dependent manner (i.e., mainly when the pathway is hyperactivated) has the potential to address the tissue-specific pathology characteristic of rheumatic diseases, including synovial hyperplasia, cartilage degradation and aberrant bone formation, with greater safety and efficacy than current biologics or JAKi. This evidence concerns the gene SOAT1 and rheumatic disorder.